Myopia Progression
Conditions
Brief summary
The Goal of the study is to evaluate the rate of myopia progression with open ring myopia control spectacle lens designs compared to a commercial peripheral plus myopia control spectacle lens (CML) in European children with myopia. This is a prospective, randomized, bilateral wear, double masked, cross-over clinical trial. There will be a total of 180 participants randomized into three groups, Group 1 - 60 participants will wear the commercial peripheral plus myopia control lens (CML). Group 2 - 60 participants will wear the Open Ring 1 (OR1) lens design. Group 3 - 60 participants will wear the Open Ring 2 (OR2) lens design. For each group, an equal balance of gender will be recruited and 50% of children will be aged between 6- 9 years old and 50% aged 10-12 years old. All groups will be required to wear spectacles for all waking hours for 12 months. After 12 months, the control group will continue wearing CML for a further 12 months; the Group 2 participants will continue wearing the OR1 lens for a further 12 months. The Group 3 participants will wear OR2 or OR3 (a modified design of OR2) based on their risk of myopia progression for a further 12 months
Interventions
OTHERmyopia control lens
Evaluation of the efficacy in decreasing myopia progression of the proposed ophthalmic lens prototypes.
Sponsors
Indizen Optical Technologies, S.L.U.
Hospital San Carlos, Madrid
University of Minho
University of Ulster
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Years to 12 Years
Healthy volunteers
Yes
Inclusion criteria
* Be aged between 6 to 12 completed years (6 and 12 years inclusive), irrespective of gender. * For each group, an equal balance of gender will be recruited and 50% of children will be aged between 6- 9 years old and 50% aged 10-12 years old. * Be cycloplegic autorefraction spherical component -0.50 D to -6.00D, cylinder no more than -2.00D, and with a spherical equivalent greater than or equal to -6.00D. * Be accompanied by parents/guardians who can read and comprehend give informed consent as demonstrated by signing a record of informed consent. * Be willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator. * Have ocular health findings considered to be "normal". * Be correctable to at least 6/9.5 (20/30) or better in each eye with spectacles. * Be willing to wear the spectacles provided by the investigators for all waking hours.
Exclusion criteria
* A known allergy to, or a history of intolerance to cyclopentolate or topical anesthetics. * Had strabismus and/or amblyopia. * Cylinder more than -2.00D * Anisometropia greater than 1.50D spherical equivalent * Had previous eye surgery (including strabismus surgery). * Any ocular, systemic or other condition or disease with possible associations with myopia or affecting refractive development e.g. Marfan syndrome, retinopathy of prematurity, diabetes. * Had any ocular injury or condition (including keratoconus and herpes keratitis) of the cornea, conjunctiva or eyelids. * Current orthoptic treatment or vision training. * Any anatomical, skin or other condition that would impact on the wearing of spectacles. * Use of or need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial. * Currently enrolled in another clinical trial. * No previous myopia management intervention or treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Myopic progression in one year | At baseline, 3, 6, 12, 18 and 24 months | This is expressed as the change in spherical equivalent refractive state from baseline levels. Spherical equivalent refraction will be taken as the mean of the spherical equivalent refraction of five, reliable, cycloplegic autorefraction measurements on each eye with a precision of 0.12D, measured in diopters (D). Myopia progression is also expressed as the change in axial length from baseline levels, measured in millimeters (mm). Myopia progression is characterized by ocular anatomical changes, the most notable being increased axial length, measured in millimeters (mm). |
Countries
Portugal, Spain, United Kingdom
Contacts
CONTACTEva Chamorro Guitierrez
Outcome results
None listed